These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35236391)

  • 1. PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough.
    Wu Z; Banya W; Chaudhuri N; Jakupovic I; Maher TM; Patel B; Spencer LG; Thillai M; West A; Westoby J; Wijsenbeek M; Smith J; Molyneaux PL
    Trials; 2022 Mar; 23(1):184. PubMed ID: 35236391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial.
    Wu Z; Spencer LG; Banya W; Westoby J; Tudor VA; Rivera-Ortega P; Chaudhuri N; Jakupovic I; Patel B; Thillai M; West A; Wijsenbeek M; Maher TM; Smith JA; Molyneaux PL
    Lancet Respir Med; 2024 Apr; 12(4):273-280. PubMed ID: 38237620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
    Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
    Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover Trial.
    Guler SA; Clarenbach C; Brutsche M; Hostettler K; Brill AK; Schertel A; Geiser TK; Funke-Chambour M
    Ann Am Thorac Soc; 2021 Dec; 18(12):2018-2026. PubMed ID: 34015241
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial).
    Martinez FJ; Wijsenbeek MS; Raghu G; Flaherty KR; Maher TM; Wuyts WA; Kreuter M; Kolb M; Chambers DC; Fogarty C; Mogulkoc N; Tutuncu AS; Richeldi L
    Am J Respir Crit Care Med; 2022 May; 205(9):1084-1092. PubMed ID: 35050837
    [No Abstract]   [Full Text] [Related]  

  • 6. Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis.
    Lechtzin N; Hilliard ME; Horton MR
    Chest; 2013 Jun; 143(6):1745-1749. PubMed ID: 23519393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis.
    Maher TM; Avram C; Bortey E; Hart SP; Hirani N; Molyneux PL; Porter JC; Smith JA; Sciascia T
    NEJM Evid; 2023 Aug; 2(8):EVIDoa2300083. PubMed ID: 38320144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis.
    Dutta P; Funston W; Mossop H; Ryan V; Jones R; Forbes R; Sen S; Pearson J; Griffin SM; Smith JA; Ward C; Forrest IA; Simpson AJ
    Thorax; 2019 Apr; 74(4):346-353. PubMed ID: 30610155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial.
    Horton MR; Santopietro V; Mathew L; Horton KM; Polito AJ; Liu MC; Danoff SK; Lechtzin N
    Ann Intern Med; 2012 Sep; 157(6):398-406. PubMed ID: 22986377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.
    Wilson AM; Clark AB; Cahn T; Chilvers ER; Fraser W; Hammond M; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett DR; Whyte M;
    JAMA; 2020 Dec; 324(22):2282-2291. PubMed ID: 33289822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
    Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
    BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Moran D; Santin-Janin H; Aubin F; Mulder GJ; Gupta R; Richeldi L
    Lancet Respir Med; 2019 Aug; 7(8):657-664. PubMed ID: 31122893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chinese herbal medicines for the treatment of cough in idiopathic pulmonary fibrosis: A protocol for systematic review and meta-analysis.
    Xiao S; Yu Y; Xiong Y; Sun F; Liu X; Yan J; Zhang S
    Medicine (Baltimore); 2020 Oct; 99(44):e22991. PubMed ID: 33126376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial.
    Martinez FJ; Afzal AS; Smith JA; Ford AP; Li JJ; Li Y; Kitt MM;
    Pulm Ther; 2021 Dec; 7(2):471-486. PubMed ID: 34152585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
    Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
    Yang SG; Yu XQ; Li JS; Xie Y; Zhang W; Ban C; Feng J; Wu L; Lu X; Zhao L; Meng Y; Zhou M; He Y; Luo W
    Trials; 2022 Sep; 23(1):725. PubMed ID: 36056382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
    Podolanczuk AJ; Kim JS; Cooper CB; Lasky JA; Murray S; Oldham JM; Raghu G; Flaherty KR; Spino C; Noth I; Martinez FJ;
    BMC Pulm Med; 2022 Dec; 22(1):475. PubMed ID: 36514019
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.